Patents Assigned to CELLTAXIS, LLC
  • Method of reducing pulmonary exacerbations in respiratory disease patients
    Patent number: 11890282
    Abstract: Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: February 6, 2024
    Assignee: Celltaxis, LLC
    Inventors: Sanjeev Ahuja, Ralph Grosswald, Gregory S. Duncan, Eric B. Springman
  • Methods of inhibiting leukotriene A4 hydrolase
    Patent number: 10898471
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 26, 2021
    Assignee: CELLTAXIS, LLC
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Method of reducing pulmonary exacerbations in respiratory disease patients
    Patent number: 10898484
    Abstract: Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: January 26, 2021
    Assignee: CELLTAXIS, LLC
    Inventors: Sanjeev Ahuja, Ralph Grosswald, Gregory S. Duncan, Eric B. Springman